Sun Pharma. - Sun Pharmaceutical Industries Limited Has Informed The Exchange Regarding 'Updates'.
11/01/2019 17:00
We refer to our press release dated September 14, 2018 regarding 'Sun Pharma and SPARC Announce US FDA Approval of XELPROST to Treat Open-angle Glaucoma or Ocular Hypertension'.

Further to the above, we wish to inform you that Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, 'Sun Pharma' and includes its subsidiaries and/or associate companies) has commercialsed XELPROS (Latanoprost ophthalmic emulsion) 0.005%, in US.

The Company had in-licensed XELPROS from Sun Pharma Advanced Research Company Limited ('SPARC') in June 2015 and this commercialization of XELPROS, has triggered a milestone payment of USD 10 Million and sales linked royalties, by the Company to SPARC.

This is for your information and record.